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Summary
Endothelins are peptides, originally isolated from endothelial cells, with potent vasoactive and
mitogenic properties. In this study, we demonstrate that human macrophages synthesize and
secrete endothelins. Cultured human macrophages were found by immunocytochemistry to stain
positively for endothelin 1 and endothelin 3. Theircapability to produce and release these peptides
was confirmed by a combination of reverse-phase high-performance liquid chromatography and
radioimmunoassays, specific for endothelin 1 and 3, respectively. Immunoreactive peptides were
identified both in cellular extracts and in macrophage-conditioned medium. The secretion of
endothelin 1, but not of endothelin 3, from macrophages could be stimulated 6-10-fold by
lipopolysaccharide or phorbol myristate acetate (PMA). Northern blot analysis oftotalmacrophage
RNA using an endothelin 1 cDNA probe revealed induction of endothelin mRNA in PMA
treated macrophages. Furthermore, immunoreactive endothelin 1 and 3 were found in U937
cells, a human promonocytic line, and in freshly isolated human monocytes. In contrast, no
immunoreactive endothelin was detected in cell extracts from human neutrophils and lymphocytes.
The expression of endothelins in tissue macrophages was demonstrated in paraffin sections of
human lung using immunohistochemistry. In conclusion, the finding that human macrophages
produce endothelins suggests an important role for these peptides in the microenvironment of
tissue macrophages. Macrophage-derived endothelins may have an essential function in blood
vessel physiology, and aberrant production may contribute to vessel pathology.
T
he endothelins, a recently discovered family of peptides,
are potent vasoconstrictors of mammalian blood vessels
(1). Endothelin 1 was originally isolated and sequenced from
the supernatant of cultured porcine aortic endothelial cells
(2), while the existence of endothelin 2 and 3 was predicted
after the isolation of genes related to endothelin 1 (1). En-
dothelins can affect blood vessels of all sizes and types (3),
including lymphatic vessels (4), and can also act on other
smooth muscle cells, such as those in the bronchial tree (5).
In addition, endothelins are mitogenic for vascular smooth
muscle cells and fibroblasts, and potentiate growth factor-
stimulated DNA synthesis in these cells (6-11). These prop-
erties, alongwith the observation, both in vivo and in vitro,
that blood vessels with intact endothelial lining are respon-
sive to the vasoactive effects of endothelins only upon their
application to the adventitia (12, 13), seem to favor a role
for endothelins in the regulation of a certain microenviron-
ment rather than as circulating hormones. Moreover, they
provoke the search for a source of endothelins other than en-
dothelial cells.
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We describe here the expression of endothelins by human
macrophages, cells that, by virtue of their ability to present
antigen, their secretion of soluble products, and their phago-
cytic capabilities, are involved in the physiological regulation
oftheir microenvironment and often reside within or in close
proximity to blood vessels. These findings further illustrate
the potentially far reaching role of endothelins in cell biology.
Materials and Methods
Cells. Human monocytes/macrophages were obtained from
PBMC that had been separated from freshly drawn blood using
Ficoll-Hypaque. Cells were seeded at a density that allowed them
to grow to confluence in T75 flasks (-4 x 106 cells/ml; for ex-
traction procedures) or to stay distinctly subconfluent on glass slides
(N2 x 106 cells/ml; for immunohistochemistry). Monocyte/
macrophagestarting and maintenance media, whichcontain a pro-
prietary formulation of granulocyte/macrophage CSF and macro-
phageCSF, were used according to the manufacturer's recommen-
dation (Pan Data Systems, Rockville, MD). In brief, cells were
initially diluted in starting medium, added to the culture dishes,
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1741-1748and allowed to sit undisturbed for 3 h at 37°C. Plates were then
gently swirled to resuspend nonadherent cells before the medium
was removedandreplaced by maintenance medium (supplemented
with 15% FCS and 2 MM L-glutamine), which was not changed
during the first week of culturing. In 2-3-d intervals, when the
medium began to turn yellow, fresh medium wasadded to the old
medium. After 1wk, the maintenance medium wasexchangedevery
other day. Cells were used for experiments between day 10 and
16 after seeding. At this time, oneT75 flaskcontained aconfluent
layer of N3-4 x 10' cells, with some variance in numbers from
donor to donor. For each experiment, only cells derived from one
donor were used. The purity of our cultures, as determined with
nonspecific esterase stain (Technikon, Tarrytown, NY) and/or anti-
Leu-M5 (BectonDickinson&Co., Mountain View, CA), wasusu-
ally >95%. At least 12 h before each experiment, cells were trans-
ferred into serum-free medium (RPMI 1640, containing 2 mM
L-glutamine). For stimulation experiments, 10 Wg/mlof LPS(Esch-
erichia coli; Calbiochem-Behring Corp., La Jolla, CA), 10-7 M
PMA (Sigma Chemical Co., St. Louis, MO), or 5 ng/mlofTGF-0,
kindly provided by Dr. MichaelSporn, National Cancer Institute,
were added to themedium. Six to eight flasks were treated in par-
allelwith onestimulant andalways compared with an equalnumber
of nontreated flasks. Monocytes were obtained by elutriation of
PBMC. T lymphocytes were purified from peripheral blood and
tonsil mononuclear cells using the SRBC rosette technique (14).
Blymphocytes were obtained from tonsil mononuclear cells by nega-
tive selection viarepeated rosettingwith SRBC (14). Thecell popu-
lations were >98% pure as assessed by FACS analysis. Neutrophils
were obtained by Percollgradient centrifugation, andplatelets from
NIHbloodbank platelet concentrates. U937,ahuman myelomono-
cytic cell line (15), was maintained in RPMI 1640, supplemented
with 10% FCS, 2 MM. L-glutamine, and 0.02 M Hepes. Sheep
choroid plexus cells were purchased from American Type Culture
Collection (Rockville, MD).
Immunocytochemistry ofCultured'Cells.
￿
Macrophages grown on
glass slides to <80% confluence were fixed in methanol (-20°C,
10 min) and treatedwith 10% normal goat serum (roomtempera-
ture [RT],t 20 min) to reduce nonspecific background staining.
Rabbit anti-endothelin 1 and, alternatively, anti-endothelin 3 an-
tibody (Peninsula Laboratories,Inc., Belmont, CA) (1:100, RT, 180
min) were used as the first antiserum and rhodamine-labeled goat
anti-rabbit IgG(Boehringer Mannheim Biochemicals, Indianapolis,
IN) (1:1,000, RT, 30 min) as the second antiserum. To test the
specificity of the immunohistochemical reaction, normal rabbit
serum or antiserum, preabsorbed with synthetic endothelin 1 or
3 (Peninsula Laboratories, Inc.), were substituted for the primary
antiserum.
Imniunohistochemistry ofParaffin Sectionsfrom Human Lung Tissue.
Human lung tissue forhistological examinations wasobtained from
open lungbiopsy, surgery, or autopsymaterial. After rehydration,
theimmunogold silver staining method was performed according
to the manufacturer's protocol (Janssen Biotech NV, Olen, Bel-
gium). Anti-endothelin 1 and 3 antisera, respectively, were used
as primaryantiserum(Peninsula Laboratories, Inc.) (1:100; RT, over-
night). Fornegative controls, normal rabbit serum was substituted
for theprimary antisera. Sections were counterstained with Harris's
hematoxylin.For comparison, hematoxylin andeosinstaining was
done on representative sections of each specimen.
Extraction and Chromatographic Procedures.
￿
The serum-free mac-
rophage-conditioned medium was centrifuged (2,000 g, 10 min,
1 Abbreviations used in thispaper: BAL, bronchoalveolar lavage; kT, room
temperature; TFA, trifluoroacetic acid.
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2°C) and concentrated by extraction through a Sep-Pak C18 car-
tridge (Waters Associates, Milford, MA), pretreated with 60%
acetonitrile containing 0.1% trifluoroacetic acid (TFA). The re-
tained material was washed with 0.1% TFA, eluted with 60%
acetonitrile/0.1% TFA, and speed-vac dried. For HCl extraction,
cells were washed two times in cold PBS. Hot 0.1 N HCl (N3
ml/108 cells) was added to the cell pellet. The suspension was
mixed, boiled in a waterbath for 4 min, and immediately put on
ice. The cells were sheared with a polytron, and the suspension
wascentrifuged (3,000g, 15 min, 2°C). The supernatant was col-
lected andlyophilized.Theextracts were analyzed by reverse-phase
liquid chromatography using a 3.9-mm x 30-cm, 300-ti pore,
15-/Aparticle, C18Delta-Pakcolumn (WatersAssociates). The pep-
tides were eluted with a linear gradient of 5-50% at 70 min and
100% at 80 min with acetonitrile (Burdick & Jackson Laborato-
ries, Inc., Muskegon, MI) containing 0.1% TFA(Pierce Chemical
Co., Rockford, IL)at aflow rate of 1 ml/min. Data were collected
and analyzed with a photodiode array detector (990; Waters As-
sociates) andchromatographic work station. Fractions (1 ml) were
collected, splitinto two equalaliquots, speed-vacdried, redissolved
in RIA buffer, and analyzed by either an endothelin 1 or 3 RIA
(Peninsula Laboratories, Inc.). The detection limit of both assays
was 1 pg/tube. The endothelin 1 RIA showed a crossreactivity
with human big endothelin (the endothelin 1 precursor) of nearly
20%. Recoveries of standard endothelins (Peninsula Laboratories,
Inc.) from extracted cells and media were 75-80% and 65-75%,
respectively, with a slightly better recovery of endothelin 1 from
extracted media as compared with endothelin 3. For screening of
other selected hematopoieticcellsfor endothelin immunoreactivity,
lyophilized HCl extracts were redissolved in RIA buffer, pH ad-
justed, and exposed directly to RIA.
Northern BlotAnalysis.
￿
Totalcellular RNA wasextractedfrom
nontreated andPMA-treated (20h) macrophages and from human
lung tissue (obtained from a patient with Wegener's granuloma-
tosiswho underwentlung surgery) using theguanidinium thiocy-
anate/cesium chloride method (16) . 12 gg of RNA was separated
on adenaturing formaldehyde 1% agarose gel, transferred to nylon-
supported nitrocellulose membranes, UV crosslinked, andhybrid-
ized with a cDNA probe forendothelin 1 (kindly provided by Dr.
Kenneth D. Bloch, Boston, MA) (17), which waslabeled with "P-
dCTP via arandom primingkit (Pharmacia Fine Chemicals, Upp-
sala,Sweden).Northernblotswere washedtwicein 2x SSC; 0.1%
SDS at room temperature, and twicein 0.1x SSC, 0.1% SDS at
52°Cfor20 mineach. Autoradiographywasperformed at -70°Cby
exposing the blots to Kodak X-omat AR films for 24 h.
Results
Endothelins in Cultured Human Macrophages.
￿
Immunocy-
tochemistry ofcultured macrophages revealed apositive signal
for endothelin 1 and 3 in >95% of the cells (Fig. 1). The
cellular signal distribution pattern was similar for the two
antisera with pronounced perinuclear staining. Replacement
of the antisera by normal rabbit serum or antisera that had
been preabsorbed with syntheticendothelins resulted in anega-
tive staining pattern (Fig. 1):
Thepresence ofendothelin 1 and3in extracts of cultured
human macrophages and in macrophage-conditioned media
was confirmed utilizing a combination of HPLC and RIA
specific for endothelin 1 and3, respectively (Fig. 2). Reverse-
phase HPLC profiles of endothelin 1-like immunoreactivityFigure 1 .
￿
Immunofluorescent staining ofcul-
turedhuman macrophages (x400) with anti-en-
dothelin 1 antiserum (a), anti-endothelin 3 an-
tiserum (b), and normal rabbit serum (c) .zZ
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Figure 2 .
￿
Reverse-phase HPLC profiles of endothelia 1 (top) and en-
dothelin 3 (bottom) immunoreactivity in extracts ofculturedhuman macro-
phages (equivalent of a confluent cell layer in one T75 flask; dotted line)
and macrophage-conditioned medium (from the same T75 flask ; 20 h,
solid line) . The arrows indicate the elution positions ofsynthetic endothelin
1 (1), endothelin 3 (3), and human big endothelin (B), respectively.
resulted intwo major peaks eluting with the same retention
time as standard endothelin 1 and its precursor form, big en-
dothelin, respectively . Endothelin 3-like immunorewtivity
showed a distinct peak at the elution position of standard
endothelin 3 and a second peak, occurring earlier, whose na-
ture remains to be determined. Sincemany macrophage-derived
peptides and proteins are increased after stimulation, we used
Figure 3 .
￿
Reverse-phase HPLC profiles of endothelia i immunoreac-
tivity in macrophage-conditioned media (medium equivalent ofone T75
flask/condition ; 26 h) under basal and stimulated (PM, 10-7M; LPS,
10 wg/ml) conditions . The arrows indicate the elution position of syn-
thetic endothelin 1 (1) and human big endothelin (B), respectively.
Figure 4 .
￿
Northern blot analysis oftotalRNA fromPMAtreated (lane
2) andnontrated(lane1) macrophages, and from human lung tissue (lane
3) using an endothelia 1 cDNA probe.
the combination HPLC/RIA to specifically measure the
amounts of endothelia 1- and 3-like immunoreactivity in
macrophage-conditioned media after treatment of the cells
with either LPS (10 Ftg/ml), PMA (10 -7 M), or TGF-(3 (5
ng/ml) for 20 h . Both LPS and PMA treatment resulted in
a marked increase in endothelin 1 secretion (Fig. 3) . Ofnote
is the fact that the big endothelia peak, which is distinct
under basal conditions, could not be distinguished after stim-
ulation o£ the cells with LPS or PMA . From a basal level
of 11 pg/ml, LPS induced a sixfold increase of endothelin
1 to 65 pg/ml .The rise afterPMA treatment was even more
striking, approaching 10-fold ower baseline. In contrast, TGF-0
had no effect on the baseline production of endothelin 1 . En-
so
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Figure S .
￿
Reverse-phase HPLC profiles of endothelin 1 (solid line) and
endothelin 3 (dotted line) immunoreactivity in extracts of cultured human
macrophages (confluent cell layer in one T75 flask), U937 cells (4 x 107
cells), and human peripheral blood monmytes (4 x 107 cells) . The arrows
indicate the elution positions of syntheticendothelin 1(1) and endothelin
3 (3), respectively.
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clearly affected by any of the compounds tested (data not
shown) . Northern blot analysis of total macrophage RNA
using an endothelin 1 cDNA probe showed a distinct 2.5-kb
band in PMA-treated cells that was not visible in unstimu-
lated cells (Fig . 4) .
Endothelins in Other Hematopoietic Cells.
￿
In addition to cul-
tured macrophages, endothelins were also detected in cell ex-
tracts from freshly isolated monocytes and from U937 cells,
ahuman promonocytic line. Reverse-phase HPLC profiles of
endothelin 1- and 3-like immunoreactivity in these extracts
displayed a pattern very similar to that seen in cultured mac-
rophages (Fig . 5) . Table 1 gives the results of a screening by
RIA of other hematopoietic cells for endothelin 1 and 3
immunoreactivity. While PBMC, purified monocytes, and
platelets displayed endothelin immunoreactivity, neutrophils,
as well asT and B lymphocytes, were negative. Sheep choroid
1745
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Figure 6 .
￿
Immunogold-silver staining of paraffin
sections of human lung tissue (obtained from a pa-
tient with Wegener's granulomatosis ; x500) with
anti=endothelin 3 antiserum (a), and normal rabbit
serum (b) . While a shows positive staining of both
intraalveolar macrophages and alveolar epithelial cells,
no staining is seen in the control specimen (b) .
plexus cells had been found previously to contain immunoreac-
tive endothelins (Ehrenreich et al., unpublished observations)
and were used as an additional positive control in this assay.
Examination ofHuman Lung Tissue .
￿
Using immunohisto-
chemistry, alveolar macrophages showed distinctly positive
staining for endothelin 1 and 3 (Fig. 6) . In addition, in agree-
ment with recent reports on a number of animal species (18,
19), human airway epithelium was found to stain positively
for both peptides (Fig. 6) . Northern blot analysis of total
RNA from human lung tissue detected a very strong 2.5-kb
band and a weaker band of -3.7 . kb (Fig. 4) . In rat lung,
the presence ofboth a 2.5- and a 3.7-kb form of endothelin
mRNA has been reported previously and has been ascribed
to the transcription of endothelin 1 and 3, respectively (20) .
If this was the case in the human system as well, it would
indicate a degree of crosshybridization of the endothelin 1
cDNA probe with endothelin 3 mRNA .Table 1.
￿
Comparison of Endothelin 1 and 3 Immunoreactivity
in Human Monocytes and Other Selected Hematopoietic Cells
Experiments were repeated two to three times each with consistent results.
The data are from one representative experiment.
Discussion
The present study demonstrates the presence ofimmuno-
reactive endothelin 1 and 3 in cultured human macrophages
and macrophage-conditioned medium, as well as in cellular
extracts from human peripheral blood monocytes and U937
cells, a humanpromonocytic line. In contrast, no immunoreac-
tive endothelinwas detectable in lymphocytes or neutrophils;
however, platelets showed positive immunoreactivity. The ab-
solute concentrations of endothelins in monocytes and mac-
rophages seem to vary somewhat among individual healthy
donors, which could well be related to the varying state of
activation of monocytes in different individuals.
Incubation of macrophages with LPS and PMA resulted
in an increase ofendothelin 1 secretion by 6-10-fold. In addi-
tion, Northern blot analysis of totalmacrophage RNA using
an endothelin 1 cDNA probe revealed a distinct 2.5-kb mRNA
transcript upon stimulation of the cellswith PMA. Consis-
tent with this observation, the 5' flanking region ofthe human
endothelin 1 gene contains consensus sequences for the phorbol
ester-responsive element (21). In endothelial cells, however,
endothelin 1 secretion was not increased by PMA (22). In
contrast, TGF-0, which did not affect macrophage-derived
endothelin 1 in our study, represents a potent stimulator of
endothelin 1 message in endothelial cells (23) . This suggests
that the signals for productionof this peptide may vary among
cell types. In contrast to our findings with endothelin 1, en-
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dothelin 3 levels in macrophage-conditioned medium were
not significantly modulated by any ofthe compounds tested.
Since the two peptides are coded for by different genes (1),
they may be independently regulated. In fact, their different
potencies with respect to their vasoconstrictive or mitogenic
effects, and their different affinity for and biologic activity
at a particular receptor (3, 5, 24-26), point to different phys-
iological roles for these peptides.
In contrast to recent findings of others and ourselves (27,
28) showing the simultaneous expression ofendothelin and
endothelin receptors in primary astrocytes, implying the pos-
sible existence of an autocrine control mechanism in these
cells, cultured human macrophages did not specifically bind
either endothelin 1 or endothelin 3 (Ehrenreich et al., un-
published observations). furthermore, T and B lymphocytes
from peripheral blood or tonsils that are devoid o¬endothelin
immunoreactivity also failed to show any specific endothelin
binding. Therefore, at least under basal conditions, lympho-
cytes are not likely to be major sources of or targets for en-
dothelins. Given the fact that under normal physiologic con-
ditions, and even more so in inflammatory states, macrophages
are found in close proximity to vascular smooth muscle cells,
fibroblasts, or mesangial or glial cells, all of which possess
endothelin receptors (6-11, 27-29), these cells are potential
targets for the actions of macrophage-derived endothelins.
To delineate the potential in vivo relevance of our findings
with monocytes/macrophages, we examined human lung
tissue and noted distinct immunohistochemical staining of
alveolar macrophages for endothelin 1 and 3. Since the lungs
apparently play a major role in the clearance of endothelins
from the circulation (30, 31), alveolar macrophage endothelin
might represent a peptide that has been adsorbed by these
cells. The fact, however, that cultured macrophages express
endothelin 1 mRNA and can be specifically stimulated to
secrete endothelins, together with the identification of en-
dothelins in monocytes and U937 cells, strongly argues that
endothelin detected in tissue macrophages is at least in part
synthesized in situ. Interestingly, in a recent pilot study, we
detected immunoreactive endothelin 1 in bronchoalveolar la-
vage (BAL) samples of patients with Wegener's granuloma-
tosis and lung involvement, as well as in human pleural and
peritoneal fluid samples from patients with a variety of dis-
orders (Ehrenreich et al., unpublished observations). While
the presence of immunoreactive endothelin 1 in human BAL
was reported recently (32), pleural and peritoneal fluid have
not yet been described to contain endothelins. Despite pre-
liminary evidence for a correlation between endothelin levels
and macrophage counts in these body fluids, the source of
endothelins is still not clear. Endothelial cells in these richly
vascularized areas, as well as the respiratory epithelium (18,
19) in the case of BAL, could contribute to the detectable
levels ofendothelins. Nonetheless, it is likely that macrophage-
derived endothelins do contribute significantly to the total
quantity of these peptides in conditions where large numbers
of these cells are present.
Cell type
Cell
number
Immunoreactive
endothelin 1
Immunoreactive
endothelin 3
x 106 pg pg
Platelets 4,000 12 2.1
Neutrophils
(PBMC) 12.5 ND ND
T lymphocytes
(tonsil) 7 ND ND
T lymphocytes
(PBMC) 10 ND ND
B lymphocytes
(tonsil) 7.5 ND ND
Monocytes 12.5 15 3.2
PBMC 7 9 ND
Sheep choroid
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